Q3 2023 Enovis Corp Earnings Call

Good morning, and welcome to the <unk>.

This third quarter 2023 earnings conference call.

All participants will be in listen only mode.

Should you need assistance. Please signal a conference specialist by pressing the star key followed by zero.

After todays presentation, there will be an opportunity to ask questions.

To ask a question you May press Star then one on attached on phone.

Each of withdrawal I have a question. Please press Star then two.

Please note this event is being recorded.

And I would now like to turn the conference over to Kyle Rose I know this is vice president of Investor Relations. Please go ahead.

Thank you Mary Elise and good morning, everyone. Thank you for joining us today for our third quarter 2023 results conference call.

In August as Vice President of <unk> relations.

Yeah.

So it's all our chairman and CEO as well as been Berry, our Chief Financial Officer. Our earnings release was issued earlier this morning, and it's available in the investors section of our website <unk> com, we will be using a slide presentation in today's call, which can also be found on our website.

The audio and the slide presentation of this call will be archived on our website later today.

During the call, we'll be making some forward looking statements about our beliefs and estimates regarding future events and results. These forward looking statements are subject to risks and uncertainties, including those set forth in the safe Harbor language in today's earnings release and in our filings with the SEC actual results might differ materially from any forward looking statements.

We make today.

We're looking statements speak only as of today, and we do not assume any obligation or intend to update them, except as required by law with respect to any non-GAAP financial measures referenced during the call today. The accompanying reconciliation information relating to those measures can be found in our earnings press release and in the appendix of today's slide.

Presentation with that let me turn it over to Matt who will begin on slide three.

Thanks, Kyle Hello, everyone and thanks for joining us today as.

As we previously announced we had a very productive third quarter with continued share gain solid margin expansion and we announced the strategic acquisition of Lima that step changes our recon business.

Let's go to slide three and talk about these highlights.

We grew organically by 6% in the quarter with 10% growth in recon and 4% growth in PNR that brings our year to date organic growth to 8%.

We continued our trend of double digit growth and share gain on the recon side versus a strong Q3 compare.

We saw a return to more normal third quarter seasonality with some summer volatility in procedure volumes from vacations, which was in line with our expectations.

We believe the elective surgery markets, we serve remain healthy with higher than normal procedural demand in 2023 overall a trend we expect will persist through 2024 and likely 2025 as pandemic related patient backlogs are gradually worked down.

Yeah.

In PNR, we had another strong quarter, showing our reestablished leadership in these markets with a bit of share gain and a stable market environment.

We expanded our adjusted EBITDA margins by 80 basis points, reflecting strong gross margin expansion from productivity.

Mix and the scaling of recent acquisitions.

In September we announced the definitive agreement to require Lima corporate.

Which expands our global reach and recon, taking that segment to about $1 billion in sales with close to 50% exposure to the faster growing extremities market.

Overall, we remain on track for a great 2023, with strong momentum versus our strategic goals.

Digging a little deeper and recap on slide four.

We had double digit growth in the U S led by 18% organic growth in hip and knee.

Extremities grew 7% against a tough prior year comp of 17% in Q3 of 'twenty two.

Outside the U S. We grew almost 12% organically in a resilient market.

I'm excited about the international growth opportunity as we expand our market position with good initial traction for our industry, leading alternating in power products.

Importantly, we have strong a strong pipeline of innovation in recon that we believe will allow us to continue to take share for many years to come.

The ramp of our empower revision knee remains in the early innings and we also have launched an updated August 2.0, with full and power capability.

Additionally, in foot and ankle, we recently launched the evolve 34, lapidus correction system for Bunions, one of the fastest growing market segments in the U S.

We've had terrific feedback from surgeons all three of these great new products.

Turning to slide five I want to take a moment to remind everyone about the exciting opportunity we have to advance our business with the acquisition of <unk>.

I was recently in Italy, and Switzerland meeting with the Lima, and math its leaders and teams, we're making good headway on our integration planning activities and I came away with increased conviction and excitement about the strength of the talent and the big opportunity that we haven't had.

We have a lot of experience and track record doing acquisitions, well and are following our proven E. G X playbook to make sure. This one gets off to a great start and deliver strong strategic impact financial contributions and shareholder returns.

The addition of Lima represents the next step in the evolution of the Novus as we execute against our strategic goal to build a high growth Med Tech innovator with a clear pathway for sustained operating margin expansion.

This transaction, which is expected to close in early 2024 will reshape our mix to faster growing higher margin recon and increased our exposure to the fastest growing parts of the recon market in extremities.

This accelerates our progress against our long term strategic pillars of sustainable high single digit organic growth continuous margin expansion and global scale.

Okay.

In PNR on slide six our 4% organic growth reflects a healthy market environment and disciplined execution.

This business is performing in line with our strategic plan.

Global bracing Roche is over 4% year to date with share gain from strong customer service, improving innovation and motion M D clinic conversions.

We have a strong pipeline of innovation to drive additional growth, including a new OA knee brace called Rome, and the next generation of clinical electric therapy products for a recovery Sciences team.

Gross margins in this segment expanded by 150 basis points as we continue to sustained traction on price versus cost and roll out additional eject business system tools, which are driving notable productivity improvements.

Moving to slide seven before I hand, it over to bad I want to reiterate our confidence in the team's execution year to date, we have a diverse global business and while 2023 is thankfully been a bit more normal than recent years. It takes a lot of day to day execution from our team members around the world to consistently deliver the way we have.

Our execution in 2023 shows our commitment and capability to create compounding shareholder value through high single digit organic growth and continuous margin expansion.

The high single digit growth comes from our demonstrated ability to consistently grow recon double digits, along with our stable low to mid single digit PNR growth.

The margin expansion comes from the stroke structural gross margin expansion as we grow recon faster supplemented by E T X productivity and scale, partially offset by growth investments and in your headwinds.

We will provide a more formal update for 2020 for guidance on our fourth quarter call, but we are confident in our ability to continue to drive this compounding growth in margin Formula and also ramp up the impact of recent acquisitions.

Now I'll, let Ben take you through the P&L details and the guidance increase Ben Thanks.

Thanks, Matt and Hello, everyone I'll begin my remarks on slide eight.

We're pleased to report third quarter sales of $418 million up 9% versus prior year and 6% organic.

Our growth was fueled by strong demand for our products and solid commercial execution in both of our business segments.

Additionally, our third quarter sales results include a combined 260 basis point positive contribution from foreign currency and recent acquisitions.

Third quarter gross margin was 58, 2% up 140 basis points year over year.

The growth was driven by leverage from higher sales strong mix and cost discipline, we continue to leverage our E. G X business system to stabilize and drive productivity in the supply chain and the results continue to read through in gross margin adjusted EBITDA grew 14% and adjusted EBITA Mara.

Jen was 15, 7% up 80 basis points versus prior year. This growth was driven by gross margin expansion and partially offset by growth investments in R&D and dilution from recent acquisitions Q3 results build on our strong first half, resulting in year to date adjusted EBITDA.

Margins up 100 basis points versus the prior year.

Third quarter effective tax rate was 19% compared to 6% last year, which included benefits from one time items that significantly lowered the rate interest expense was $6 million for the quarter versus 5 million in 2022 overall, we produced strong adjusted earnings per share of <unk>.

Six cents or 12% underlying earnings growth after normalizing for the tax and interest impacts from the prior year.

We're extremely pleased with these results and the momentum we've built this thus far in 2023 I want to congratulate all the <unk> team worldwide in delivering another strong quarter.

Let's move to slide nine.

Considering our Q3 performance, we are raising our organic sales growth outlook for the year to 7.4 to seven 6% versus the previous guidance of 7% to 7.5%. We're seeing consistent performance in both of our business segments and are excited about the momentum we are create.

And as we shape the business and build on our commercial execution efforts, we expect full year sales to be roughly 1.7 billion with approximately one point of additional growth from recent acquisitions for the year based on the latest rates, we expect foreign currency impact on sales to be.

Relatively flat we are raising the bottom end of our adjusted EBITDA range to $264 million to $270 million, reflecting our solid Q3 performance. We are updating our interest the outlook to approximately $22 million and lowering our estimated tax rate range to 90.

<unk> to 19, 5%.

Based on our strong performance in the first nine months and these adjustments we now expect our adjusted EPS to be in the range of $2 32.

$2 40 versus our previously guided $2 22.

The $2.36.

I'd like to spend the next few minutes discussing recent steps, we've taken to optimize our balance sheet and a challenging capital markets backdrop.

On slide 10, we have solidified and secured our financing for the Lima corporate acquisition, we will maintain our existing revolving credit facility and add a new term loan at our current interest rates. Additionally, we completed a convertible debt offering at a 3.8, 75% fixed rate given.

The challenging capital market conditions, we believe we have put ourselves in a strong position to drive and create value from this acquisition our effective interest rate of the company will be around five to five to $5 seven 5% based on current rates. This will allow us to deliver accretive earnings in year one.

One with meaningful accretion in year, two and beyond we will also have the flexibility to progress our integration plans and quickly position ourselves for more M&A in the future as the business scales.

To summarize on slide 11, we've had another strong quarter, leading us to again raise our full year guidance. We grew 8% sales per day in the first nine months of the year and we remain confident in our strategy and our capability to build a sustainable high single digit growth company, we took another step.

Forward and expanding our margins and we continue to execute on our clear plan for continued margin growth.

We continue to accelerate the company through M&A and have demonstrated strong execution of recent deals. We are very excited to welcome the Lima team into the <unk> family in early 2024, and look forward to creating better together.

Now I will move to Q&A Maher lease please open the call for questions.

Thank you very much we will now begin the question and answer session.

To ask a question you May press Star then one on your Touchtone phone and if you are using a speaker phone. Please pick up your handset before pressing the keys.

At any time. Your question has been addressed and you would like to withdraw your question. Please press Star then two.

At this time, we will pause momentarily to assemble our roster.

And our first question comes from Sean Brown from Wells Fargo. Zach. Please go ahead.

Hey, good morning, and thanks, so much for taking the questions and congrats on a nice print.

Just two questions for me, Matt maybe first one for you <unk> remains front and center for investors. It would be remiss of me if I didn't ask you about that so I just wanted to get your updated thoughts on how youre thinking about the impact of <unk>.

In ortho procedures, and then I had a follow up question. Please thanks.

Okay.

Thanks, a lot thanks for the kind words.

Let me address your first question and let you ask the second certainly you know we're paying close attention to all the discussion about G. L. P. One and the potential impacts.

Yeah, we've taken a look at it so far are really the you know the the demonstrated impact from G. L. P. One is on obesity and and the path of obesity and being able to reduce so obesity.

And when we look at our portfolio and we look at the portion of that portfolio that get that might be have some headwinds from myself be city versus the portion that might have some tailwind from less obesity, we would see it as you know somewhere between neutral and potentially a <unk>.

Positive.

In terms of the you know the kind of impact the G. L. P. One can have on obesity.

So that's kind of how we view it at this point based on the demonstrated impacts that are out there you know we're going to continue to monitor the situation, but you know in our business and our recon business, we get most of our growth from share gain not from the market growth itself and so even if there was a little bit of impact on the market growth in recon, our diversification as well as you know are small.

Share position in hip and knee would be a good thing in terms of enabling us to still drive very strong growth.

Great. Thanks for that comprehensive answer and then my second question was just on the backlog in orthopedic procedures.

Sort of coming up towards the end of 2023 I'm just curious as to how you think about the backlog heading into 2024 do you expect to work through that backlog next year or do you expect that to be a tailwind for some time. Thanks, so much for taking the time.

Yeah. Thanks Vik.

You know I think the way we look at this backlog topic is is that if you look at the overall industry growth.

Since our since 2019, there is still a year or two missing [laughter].

In the mass and so.

Our growth and so that that really gives an opportunity even even with some of the some of the tailwind. This year that came from from some backlog.

We still see the opportunity you know for a little bit of tailwind in each of the coming years.

If the people.

Create the capacity and the staffing to be able to work off some of that backlog and so where we're pleased that this year has had a little bit of tailwind in it particularly in the first half of the year.

In terms of recon procedures, and we would expect there's a real possibility to have that tailwind continue for the next couple of years, but obviously, it's going to be kind of situation on a year to year basis and that you will share the assumptions that we're making when we give our guidance.

Okay well proceed with.

With our next question.

Which is from Jeff Johnson from Baird, Jeff. Please go ahead.

Hey, good morning, guys.

This quarter, our I appreciate all the commentary.

Yes, Matt or Ben just on the extremities business up 7% I know it came up against that very top 17% comp just would like to hear what you're seeing maybe from a competitive standpoint, I know a couple of your competitors have launched some new shoulder products here recently, so what what are you seeing out in the field and your confidence in may be getting that number I think comps.

He is a little bit over the next few quarters, although stay pretty high do you think that gets back to a double digit number or are we kind of in this upper single digit range for the foreseeable future.

Yeah.

Yeah. Thanks, Jeff I appreciate the question.

We continue to be very confident in our leadership in shoulder. We've shown that leadership for a long time that we've been able to outgrow the market based on the you know the great I'll debate shoulder and in all the different innovation that we've been bringing through and you know certainly in the quarter. The 7% is more like.

You know in the neighborhood of market growth versus the above market rate growth that is normal, but then if you stack. It on top of 17% at last year, then you'd see kind of two years comfortably.

Comfortably above market growth. So we continue to be confident in our leadership there even in a little bit more competitive field, we still have an advantaged product in it and a tremendous innovation pipeline. Yeah. We've got a couple a couple of quarters of strong comps starting this quarter.

And at the same time, we've got some really exciting innovations coming through as we work our way through the first half of next year. So we feel comfortable that we're going to continue to show consistent above market growth in shoulder.

Over the medium term here.

Alright, that's helpful. Thanks, and then you mentioned some seasonality I think that's pretty consistent.

Consistent I'm, sorry, with everything we've heard from others as well but.

I'm sure you don't want to give month by month trends, but maybe just any thoughts from that summer seasonality how September and now into October has trended.

Are you seeing.

Some normalization of that seasonality and a recovery in volumes just kind of your.

Update on recent trend line.

Yeah sure Jeff Yeah, I mean again, it's sort of a new kind of summer seasonality said in last year with with more vacations.

And then the normal as sort of a new normal and that repeat itself.

This year.

Probably a little bit little bit heavier in in July this year than last year.

So the first couple months of the summer definitely were you know were slower.

September was a you know a good healthy step forward in October is another good healthy step forward and so we're expecting a sequential acceleration in Q4 versus Q3, and a pretty normal run to the finish you know for recon as we as we head through the coming months that will set things up well for out things rollover in the next year.

Awesome. Thank you.

And we'll take a question from young Li from Jeff Frank Young. Please go ahead.

Alright. Thank you so much for taking my question just to start maybe you wanted to hear a little bit about the early feedback from <unk>.

Your P M to Nemo customers some of those customers.

What do they like about it anything that they're cautious.

In general just how excited out there about the deal.

Yes, thanks for the question young.

We'd certainly we've spent a lot of time getting out and getting getting feedback from customers and the channel in terms of that really important combination in our recon business and a lot of very positive feedback and maybe if you. If you look at the.

Lima, Lima customers and channel.

For example here in the U S. You know they've had kind of some limitations on how much you know how much breadth of product line they've had they've had some great products, but they've had some limitations on how much breadth of product line they've had and so that's a that's a great.

A positive opportunity same goes for outside the U S. <unk> had some tremendous.

Strengths in certain areas of the product line, but also has had some some weaker areas that we will fill in very quickly and so again the customers outside the U S and the channel outside the U S are excited about the opportunity.

On the <unk> side, there's a.

There are some technologies that will come with Lima that our customers are quite excited about as well. So I'm very pleased by the feedback we've gotten from the marketplace and really excited about our about the team the time I've been able to spend with the Lima team in that or are there. Other other leaders have been spent on the spend.

At the Lima team, just a lot of great talent, there and a lot of excitement and energy about joining our company.

Okay, that's great.

I guess, maybe just to follow up on a PNR.

Yeah.

Get enough attention, sometimes but.

Pretty strong growth in the third quarter and year to date off a pretty tough comps.

It sounds like.

The market growth drove a lot of that.

But just wanted to hear a little bit about.

Some of the other key drivers of growth in the third quarter.

Any key products to call out and the sustainability, Oh got a mid single digit growth rate going forward, especially against them.

Elevated comps and also maybe on.

Our gross margins if you can comment on it.

Strong expansion of 156.

Driven by a lot of good things to talk about before.

Where are you on the P&L gross margin extension Kurt.

Yeah, Let me, let me talk a little bit about the growth and I'll, let Ben talk a little bit about the the gross margin there and we're certainly pleased with the consistent 4% growth as a leader there. We've consistently said, we don't we don't need to outgrow the market by a lot you know our strategic plan is to outgrow the market.

By by a little bit to get this.

Into that kind of low to mid single digit growth range for for PNR, and so certainly pleased with the consistent execution there.

And it is above market growth.

You know its a healthier market environment than in than in recent years and and then we've also driven nice above market growth.

And really some of that we've had very nice price performance. There that is is is helping in terms of the growth.

Second our supply chain is a very.

Strong a lot of great <unk> work in the supply chain and so the consistency of our delivery to customers. There in a demanding market. It has been has been very strong and that's the that's helping us as well third.

We've come up the curve a little bit on innovation in our PNR businesses and that's helping the team in terms of giving them. Some you know some good a good new products to sell and then fourth we continue to demonstrate.

You know some growth through motion MD clinic conversions, you know that that is a piece of our share gain in any given year and so that formula is is consistently working and getting us.

Into the kind of growth range that we need from from this this business and we're confident that as we go forward we have more innovation.

Coming through at the same time, there's a little bit of that price will start to roll off.

And so that should be able to keep us.

In the low to mid single digit growth range for PNR on it on a sustainable path, yeah and young on gross margins I mean, as Matt indicated we are taking some ground on price versus cost in terms of our ability and kind of our capabilities now to continue to try to manage through some of the inflationary impacts that we've had.

You're saying some of those pressures roll off a little bit I mean, we're getting improved freight rates.

As we kind of work through the supply chain that has helped us a little bit. The other thing is we've got some positive mix that's happening within the PNR business itself. Some of our fastest growing parts of that business actually are carrying higher gross margins. So we're getting a benefit of that on top of some of the kind of price cost.

You know head or our efforts that we've done to continue to drive improvements. So overall you put those together with all the <unk> work, that's constantly and in kind of our view them with kids, we've seen really strong performance, there and kind of feel really good about the progress on gross margin in PNR.

Alright, Thank you very much I appreciate the comprehensive answer.

Thanks, Joe.

And we'll take a question now from Bill <unk> from Canaccord.

Please go ahead.

Great. Thanks, Good morning, and thanks for taking my question.

Im going to focus on strategy. So in terms of M&A. There is a lot of moving parts going on with interest rates up in valuations down.

You've got a big deal you're closing in front of you.

I was wondering if you could help us understand one.

What do you think of M&A going into next year, given those dynamics too.

Will you buy anything with Lima kind of until that gets done three.

What do you think about valuations in the marketplace does that shift whether you go into earlier stage assets are later stage assets and then lastly, how much actually post the <unk> deal and the recent financings do you have dry powder do you actually have to buy anything.

Yeah.

Alright, thanks, Thanks, and thanks for the question a very thoughtful bill.

I think.

We're certainly very excited about the the Lima deal as well as you know some of the really important the foot and ankle and technology deals that we've done.

This year and it's definitely been a.

Better environment in terms of being able to get a better valuations on acquisitions as you've seen as we've shared the kind of multiples that we paid for those deals. So we feel like we've taken advantage of this period of time, where it's a little more of a buyers market and we had the firepower and we've made some great strategic moves.

For the company.

M&A is going to continue to be a part of our strategy, but clearly.

For the next year.

We're gonna be a you know are primarily focused on.

Continuing the integration and ramp up.

And ankle acquisitions that we've made making sure that the Lima acquisition. Our integration is a tremendous success and I would expect very likely that any any acquisitions that we do in the next six to 12 months are smaller strategic acquisitions versus anything of any any scale and size.

At the same time, we're constantly doing the strategy work too.

To prioritize.

Where else we'd be interested to make acquisitions, whether it's things that strengthen and accelerate strategies in our core markets.

Or whether it's things that would move us further into attractive.

Are there attractive ortho markets or whether it's things that would move us into attractive adjacencies that would be logical for us.

And you know we will have a little bit of firepower you know over the next year or so as we start to kind of bring back down our leverage, but probably less than around half a billion dollars ish.

And then in the coming years, we'll build that back up and can certainly consider larger an attractive strategic moves at that point in time.

Thanks.

Our next question comes from Mike Matson from Needham and company, Mike You May proceed.

Yeah. Thanks, So I guess first.

The number of acquisitions, you've done in recent years and the upcoming close of the Lima deal I imagine you've picked up quite a few implant product lines.

Yeah just.

Wanted to ask about.

If there's any plans to sort of try to rationalize some of those product lines over time, and how you go about doing that.

I know that these types of things our products tend to have a really long life cycles, and sometimes its difficult Cooper the customer loyalty aspect of certain products.

Yeah, Yeah. Thanks for the question.

Yes for sure we're taking a look at that now to be honest you know until the Lima acquisition. The majority of the stuff that we've done has not had much product overlap.

Matt This acquisition in our core recon products was largely complementary a little bit of product overlap are largely complementary and our foot and ankle acquisitions have almost all being kind of new and complementary additions with the <unk> acquisition, we certainly will get into an area, where we've got a little bit more our product line.

Lap, we still like the complementarity of the technologies and product lines and geographic positions.

And so theres not a lot of geography and product line overlap, but there certainly will be opportunities to simplify the product line over time.

We're gonna really from a we're going to focus on growth first and really focus on how and where we can cross sell and how we retain.

As much as possible of the customers and channels.

The cost efforts that will take at the outset, we will be more you know all around you know sort of.

The combinations of the businesses in the back office and in the businesses and processes.

And then over time, we'll be thoughtful about how and when we might be doing some simplification of the product lines that will will.

Scale us and make us make our growth more cash efficient over time, but we're going to do that with an eye towards making sure that we deliver very strong growth first and foremost.

Okay got it and then as far as the remote access should go was we've done some modeling.

You know, particularly with the convertible debt, having a bit lower interest rate than we'd originally kind of expected you announced the deal.

We're coming up with sort of double digit accretion in 'twenty, five and beyond EPS accretion sorry does that does that seem reasonable.

Yeah, very much so Mike and we even put I think some of that in our materials today I mean, we expect accretion in year, one and then meaningful double digit accretion starting in year two.

Okay got it thank you.

And just a reminder, if you would like to answer the question you Press Star one.

Our next question comes from Jason Wittes from Ross.

Jason Please go ahead.

Hi, yes, thanks for taking my questions.

You mentioned some pricing.

Some of your larger peers are talking about getting better pricing concessions.

In an inflationary environment are you seeing that as well and also in terms of gross margin, we did see some improvements how.

How much of that is.

Related to inflation are subsiding on the tuition.

Yeah, I'd say, Jason you know, we're seeing on both sides of the business. Some I'd say favorable pricing momentum you know one on the PNR side, where we're the market leader in weekend.

Put price increases in selective product lines, we've continued to do that over the last couple of years and we've seen some benefits there on the recon side, given we're a smaller player. We generally kind of follow what the market's doing what we're seeing is some stabilization there in terms of our pricing. So we're not seeing as much of the erosion that maybe it would.

Seen in the past, but not a whole lot of increase either but overall, we would expect that to continue and the like in an inflationary environment, probably revert back to more normalized fused kind of in more normal times.

In terms of gross margins, it's really kind of lines up with our kind of our expansion goals that we've really laid out which is one kind of getting the mix improvements of you know kind of the recon business, becoming a bigger part of our our company its getting the read through on the price versus cost the productivity.

Programs that we can can you continue to drive the leverage that we're getting from the volume growth and then the scale of the acquisitions as well. That's a you know a key component of driving our increases in gross margins as well. So all of those are contributing to the 140 basis points of expansion that we saw in the quarter.

Okay, great and on Lima, If you could maybe just review kind of sort of the key products that we should.

Be focused on it I mean, obviously the shoulders are important.

But and in distribution is very important.

Curious if you can kind of how you rank sort of the country contributors from Lima, and how we should be thinking.

Yeah sure Yeah first of all as being a very strong shoulder position with their S. M. Our shoulder.

And that's kind of.

That's going to be something that is valuable and and extendable.

The second would be they they've really that has very strong revision position.

And that's good.

Good good products in hip and knee, but very strong revision position revisions at very attractive part of the market.

And we've been earlier days in terms of our revision position in hip knee and so.

That's attractive and complementary and then the third.

Great technologies.

Around.

Three D printing there'd been a pioneer really in designing and manufacturing.

With the you know metal <unk> printing.

We have done everything from having.

Custom <unk>.

Plants that are three D printed printed for very complicated cases, which is a great tip of the spear to be able to bring to surgeons to you know to get them interested in the product line.

And at the same time, they've also use those technologies to design.

Some some great products like their revision cones for knees that take advantage of that triangular titanium proprietary.

Metal <unk> printing so that those are the that's the kind of hierarchy of some of the great products, they've gotten technologies that I would share.

Great. Thanks, I'll jump back in queue.

At this time.

We are done with our <unk>.

Question and answer session and we will then finish the conference as well we thank you very much for attending today's presentation. You may now disconnect.